BCRX vs HROW

The Advanced Deterministic Scorecard reveals significant concerns with a weak Piotroski F-Score of 2/9, indicating poor financial health, and an absent Altman Z-Score, preventing a clear distress risk assessment. Despite this, the company shows strong revenue growth of 36.1% YoY, improving operating margins, and a bullish analyst consensus of 'strong_buy' with a $20.50 target price. However, negative profit margin, insider selling, and lack of key valuation metrics like Graham Number and Altman Z-Score create substantial uncertainty. The stock trades well below its target, suggesting potential upside, but fundamental weaknesses and mixed earnings performance temper optimism.

HROW presents a stark contrast between strong top-line growth and fragile financial health, evidenced by a weak Piotroski F-Score of 2/9. While revenue growth is robust at 33.3% and analysts maintain a 'strong_buy' rating with a high target price, the company is burdened by a high Debt/Equity ratio of 4.84 and a concerning Price/Book ratio of 25.50. Insider activity is bearish, with over $9M in recent sales, suggesting a disconnect between institutional optimism and internal sentiment. The overall profile is that of a high-growth specialty pharma play with significant balance sheet risk.